StreetInsider.com News Articles

Alpha Tau Medical (DRTS) 9200 contracts of June 12.50 puts trade, share price up 18.5%

Wed, 03 Jun 2026 15:00:54 -0400

Alpha Tau Medical (NASDAQ: DRTS) 30-day option implied volatility is at 121; compared to its 52-week range of 22 to 127 with a focus on 9200 contracts of June 12.50 puts as share price up 18.5%.

Form 6-K Alpha Tau Medical Ltd. For: Jun 03

Wed, 03 Jun 2026 08:30:00 -0400

si-local-file:///var/storage/secattach/20260603/26595968.html

Form 6-K Alpha Tau Medical Ltd. For: Jun 03

Wed, 03 Jun 2026 08:30:00 -0400

si-local-file:///var/storage/secattach/20260603/26595968.html

H.C. Wainwright Reiterates Buy Rating on Alpha Tau Medical Ltd. (DRTS)

Wed, 03 Jun 2026 06:54:30 -0400

H.C. Wainwright analyst Yi Chen reiterated a Buy rating and $15.00 price target on Alpha Tau Medical Ltd. (NASDAQ: DRTS).

The analyst commented: "Yesterday, Alpha Tau Medical announced the presentation of positive overall survival and safety results from a pooled analysis of three prospective Phase 1/2 trials evaluating endoscopic ultrasound (EUS)-guided intratumoral Alpha DaRT treatment in patients with locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC) at the 2026 American Society of Clinical Oncology (ASCO) annual meeting. Of note, Alpha DaRT-treated patients who had received one prior line of chemotherapy achieved a median overall survival (mOS) of 17.0 months in metastatic

Form 6-K Alpha Tau Medical Ltd. For: Jun 01

Mon, 01 Jun 2026 09:00:00 -0400

si-local-file:///var/storage/secattach/20260601/26580276.html

Form 6-K Alpha Tau Medical Ltd. For: Jun 01

Mon, 01 Jun 2026 09:00:00 -0400

si-local-file:///var/storage/secattach/20260601/26580276.html

Barclays Starts Alpha Tau Medical Ltd. (DRTS) at Overweight

Thu, 28 May 2026 03:43:21 -0400

(Updated - May 28, 2026 3:43 AM EDT)

Barclays analyst Lukas Shumway initiates coverage on Alpha Tau Medical Ltd. (NASDAQ: DRTS) with a Overweight rating and a price target of $15.00.

The analyst comments: “We initiate coverage of Alpha Tau Medical (DRTS) with an Overweight rating and $15 price target. Alpha Tau is a biomedical company developing their Alpha DaRT radiotherapeutic implant for the treatment of various cancers. Alpha DaRT is a small, metal device that delivers localized radiation into a patient’s tumor, killing the cells. Since Alpha DaRT is not a targeted therapeutic, it is potentially tumor agnostic. DRTS's lead indication

Barclays Starts Alpha Tau Medical Ltd. (DRTS) at Overweight

Thu, 28 May 2026 03:43:21 -0400

(Updated - May 28, 2026 3:43 AM EDT)

Barclays analyst Lukas Shumway initiates coverage on Alpha Tau Medical Ltd. (NASDAQ: DRTS) with a Overweight rating and a price target of $15.00.

H.C. Wainwright Reiterates Buy Rating on Alpha Tau Medical Ltd. (DRTS)

Wed, 20 May 2026 06:47:17 -0400

H.C. Wainwright analyst Yi Chen reiterated a Buy rating and $15.00 price target on Alpha Tau Medical Ltd. (NASDAQ: DRTS).

The analyst commented: "Earlier this week, Alpha Tau Medical reported its 1Q26 financial results. Net loss was $22.9M, or ($0.26) per share, more than our estimated loss of $11.6M due to the remeasurement of warrants liability. Importantly, the company has completed patient enrollment in its U.S. multicenter pivotal ReSTART trial of Alpha DaRT for the treatment of recurrent cutaneous squamous cell carcinoma (cSCC), with 88 patients enrolled. In our view, this is a milestone towards potential future FDA pre-market approval (PMA)

Alpha Tau Medical Ltd. (DRTS) PT Raised to $8 at Piper Sandler; 'Shares are due for a breather'

Tue, 19 May 2026 09:59:27 -0400

(Updated - May 19, 2026 9:59 AM EDT)

Piper Sandler analyst Jason Bednar raised the price target on Alpha Tau Medical Ltd. (NASDAQ: DRTS) to $8.00 (from $5.00) while maintaining a Neutral rating.

The analyst commented: "Reaffirming Key Milestone Targets, More Data Coming Later this Year; DRTS reported 1Q results, including an operating loss of $13.3M (vs. Street's -$12M), while cash ended at $80M (up slightly q/q). The past 3-6 months have been fairly eventful for DRTS on the clinical and regulatory fronts, with notable headlines across each of the key indications where DRTS is allocating resources - we saw positive early

Alpha Tau Medical Ltd. (DRTS) PT Raised to $8 at Piper Sandler; 'Shares are due for a breather'

Tue, 19 May 2026 09:59:27 -0400

(Updated - May 19, 2026 9:59 AM EDT)

Piper Sandler analyst Jason Bednar raised the price target on Alpha Tau Medical Ltd. (NASDAQ: DRTS) to $8.00 (from $5.00) while maintaining a Neutral rating.

Form 6-K Alpha Tau Medical Ltd. For: May 18

Mon, 18 May 2026 16:32:00 -0400

si-local-file:///var/storage/secattach/20260518/26514413.html

Form 6-K Alpha Tau Medical Ltd. For: May 18

Mon, 18 May 2026 16:32:00 -0400

si-local-file:///var/storage/secattach/20260518/26514413.html

Alpha Tau Medical Ltd. (DRTS) Misses Q1 EPS by 14c

Mon, 18 May 2026 16:22:59 -0400

Alpha Tau Medical Ltd. (NASDAQ: DRTS) reported Q1 EPS of ($0.26), $0.14 worse than the analyst estimate of ($0.12).

For earnings history and earnings-related data on Alpha Tau Medical Ltd. (DRTS) click here.

Alpha Tau Announces First Quarter 2026 Financial Results and Provides Corporate Update